Oculis
Executives
View the org chart displaying its 15 main executives
Most searched biographies at Oculis
- Riad Sherif, Chief Executive Officer and Director
- Pravin Dugel, Director
- Geraldine O'Keeffe, Director
Popular executive movements at Oculis
- Snehal Shah has joined the company as President of Research & Development (posted on April 12 2024).
- Ramin Tadayoni has joined the company as Chief Scientific Officer (posted on March 1 2024).
- Rebecca Weil has joined the company as Chief Commercial Officer (posted on September 12 2023).
Create your alert
to follow the executive moves at Oculis.
Pharmaceuticals
Oculis has 1,860 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- MedMen has filed for bankruptcy protection (posted on April 28 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Oculis
- Oculis Reports Q3 2023 Financial Results and Provides Company Update | Oculis
- News Releases | Oculis
- Oculis to Present at Upcoming November Investor Conferences | Oculis
- Oculis to Present a Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edema | Oculis
- Oculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular Edema | Oculis
- Positive Phase 3 Stage 1 DIAMOND Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress | Oculis
- Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase | Oculis
- Oculis to Present at Upcoming September Investor Conferences | Oculis
- Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update | Oculis
- OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery | Oculis
- View more press releases Close
Social media about Oculis
- Oculis on Wikipedia, Google News & Yahoo Finance
- Oculis on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Riad Sherif 
